[211 Pages Report] The global chemotherapy-induced myelosuppression treatment market stands at a net worth of US$ 8.06 Billion in 2022, and is predicted to rise at a CAGR of 3.3% over the forecast period to attain a valuation of US$ 9.78 Billion by 2028.
| Attributes | Details |
|---|---|
| Chemotherapy-Induced Myelosuppression Treatment Market Size (2022) | US$ 8.06 Billion |
| Sales Forecast (2028) | US$ 9.78 Billion |
| Global Market Growth Rate (2022 to 2028) | 4.6% CAGR |
| Share of Top 5 Market Players | 50% |
Chemotherapy-induced myelosuppression treatment accounted for 6.5% share of the global cancer immunotherapy market in 2021.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 3.23% |
| H1, 2022 Projected | 3.26% |
| H1, 2022 Outlook | 3.16% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 07 ↓ |
The market for chemotherapy-induced myelosuppression treatment is subject to changes as per regulatory dynamics and product safety impositions, in lieu of the macro and industry standards.
The comparative analysis and market growth rate of global chemotherapy-induced myelosuppression treatment market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 10 BPS, and, a negative BPS growth is expected in H1-2022 over H1- 2021 duration with 07 Basis Point Share (BPS).
The dip in the BPS values is associated with increased healthcare resource utilization for the treatment of chemotherapy induced myelosuppression, thus incurring high costs associated with treatment. With increasing use of supportive care interventions and associated burden of cost to the patient, the market observed a decline in the BPS values, owed to lower patient preference for the treatment modality.
The key development in the market includes the introduction of COSELA™ (trilaciclib), which is the first approved myeloprotection therapy. With the advent of novel therapies for chemotherapy-induced myelosuppression treatment, the market is expected to observe a positive growth outlook during the forecast period.
“Need for Early Diagnosis & Reduction in Cancer Mortality Driving Market Growth”
During the historical period of 2013 to 2021, the chemotherapy-induced myelosuppression treatment market expanded at a CAGR of 3%.
Chemotherapy-induced myelosuppression is lesser ability of bone marrow to produce blood cells (WBC, RBC, and platelets). This mostly occurs in cancer patients as an adverse effect of chemotherapy drugs, especially in those cases that are located near the bone marrow or larger bones with cavities.
Chemotherapy-induced myelosuppression can result in decreased production of red blood cells (anaemia), white blood cells (leukopenia), and platelets (thrombocytopenia).
Significant research & development activities have resulted from the growing incidence of leukaemia, prompting various pharmaceutical and drug corporations to invest in cancer-related research. The rapidly increasing rate of anaemia and thrombocytopenia among the elderly population base will also benefit industry dynamics.
The growth of the chemotherapy-induced myelosuppression treatment market can be majorly attributed to the increasing availability of comparatively cost-effective biosimilars in the chemotherapy-induced myelosuppression treatment market.
The global chemotherapy-induced myelosuppression treatment solutions market is anticipated to rise at a CAGR of 3.3% from 2022 to 2028.
“Extensive Drug Pipeline Likely to Increase Availability of Cost-Effective Products for Chemotherapy-Induced Myelosuppression Treatment”
Growing emphasis on the research and development of drugs and therapies for chemotherapy-induced myelosuppression treatment in conditions such as neutropenia, anaemia and thrombocytopenia, is expected to create significant growth opportunities in the chemotherapy-induced myelosuppression treatment market.
Growing R&D expenditure by pharmaceutical industries for the various drugs used for chemotherapy-induced myelosuppression treatment is expected to boost the product pipeline.
Presence of various clinical-stage pharmaceutical companies, which are focusing on the development of novel drugs for chemotherapy-induced myelosuppression treatment, is expected to be a major forecast impact factor.
Cancer is the second-leading cause of death worldwide. Global availability of advanced treatment options such as chemotherapy, radiotherapy & surgical procedures is also boosting the chemotherapy-induced myelosuppression treatment market.
Early diagnosis of cancer has enhanced the treatment-seeking rate in the developed world, which is, in turn, a major driver of the chemotherapy-induced myelosuppression treatment market.
Chemotherapy-induced myelosuppression treatment holds significant potential for revenue generation in developing countries owing to improving treatment-seeking rates and improving product availability.
Principal Consultant
“Long Process for Approval of Drugs for Myelosuppression Treatment”
The market is being disrupted by the lengthy approval procedure for medications for myelosuppression treatment. The high cost of medications, as well as other demanding regulatory processes, are posing further challenges to the market growth.
A metallic taste, redness, muscle aches, and arthralgia, as well as the possibility of allergic responses are all common adverse effects of iron therapy. In addition, loss of patent protection and strong competition may impede market expansion.
“Rising Investments in R&D for Myelosuppressive Therapies Driving Market Growth in North America”
North America is leading the global chemotherapy-induced myelosuppression treatment solutions market. The market will gain traction with significant increase in R&D spending for myelosuppressive therapies and the existence of a well-established healthcare industry.
Rising cancer prevalence, expanded infrastructure, and increased healthcare awareness are some of the reasons driving market expansion in this region. Favorable reimbursement rules, robust commercial operations, and a large patient pool are driving the growth in North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Prominent Presence of Cancer Therapeutics Providers in the U.S.”
The market in the U.S. is likely to expand at a rapid pace over the forecast period. The presence of top cancer therapy providers, large R&D investments, and developed healthcare systems are driving the market growth in the U.S.
Rising cancer burden in the United States has created numerous growth prospects for top cancer therapeutics providers, resulting in increased product demand.
“Rising Penetration of Advanced Cancer Care Treatments”
The China chemotherapy-induced myelosuppression treatment products and services market is speculated to exhibit a high growth owing to numerous initiatives taken by various organizations to enhance awareness, educate the public, and raise finances for chronic diseases.
Industrial growth, rising senior population and cancer prevalence, rising disposable income, and rapid deployment of advanced cancer care treatments are all contributing to the market growth in China.
“Chemotherapy-Induced Myelosuppression Therapies Widely Employed for Treatment of Neutropenia”
Neutropenia indication is expected to account 61.6% share of the chemotherapy-induced myelosuppression treatment market in 2022. The global chemotherapy-induced myelosuppression treatment market is classified into three categories based on the indication: anaemia, neutropenia, and thrombocytopenia.
Neutropenia is a blood disorder characterized by decreased neutrophil counts, which are white blood cells that protect the body from infection. One of the most common side effects of chemotherapy is neutropenia, which can lead to life-threatening infections if left untreated.
“Higher Effectiveness of Erythropoietin Stimulating Agents in Myelosuppression Treatment”
Market share of erythropoietin stimulating agents will grow as the number of instances of anaemia rises, according to pharmacological class. According to the World Health Organization (WHO), anaemia affects more than 1.62 billion people worldwide, accounting for 24.8% of the total population.
These drugs not only reduce transfusion rates but also enhance cognition. They also reduce the need for blood transfusions and are often used by physicians for their cancer patients undergoing chemotherapy to ensure a better quality of life. Erythropoietin stimulating agents are also commonly utilized to boost red blood cell formation in the bone marrow.
The COVID-19 pandemic has had an impact on every industry, including healthcare. Because of the delayed commercial activity across numerous industrial verticals as a result of the COVID-19 crisis, the world economy was severely disrupted. Due to increased hospital admissions and limited healthcare facility visits to combat the rising infection rate, the chemotherapy-induced myelosuppression treatment market saw a moderately lower demand.
However, the rising number of patients with lung cancer and other cancers that are more susceptible to infection as a result of the virus has given the industry a boost. The growing demand for a variety of treatment options to reduce the risk of anaemia or thrombocytopenia is expected to drive market growth over the coming years.
Ley manufacturers of chemotherapy-induced myelosuppression treatment devices are focusing on increasing their geographical footprint as well as launching new products to increase their revenue generation in the chemotherapy-induced myelosuppression treatment market.
For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Value in US$ Million |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
Chemotherapy-Induced Myelosuppression Treatment Market by Indication:
Chemotherapy-Induced Myelosuppression Treatment Market by Drug Class:
Chemotherapy-Induced Myelosuppression Treatment Market by Route of Administration:
Chemotherapy-Induced Myelosuppression Treatment Market by Distribution Channel:
Chemotherapy-Induced Myelosuppression Treatment Market by Region:
The global chemotherapy-induced myelosuppression treatment market is valued at US$ 8.06 Bn in 2022, and is projected to reach US$ 9.78 Bn by 2028.
Novartis AG, Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Myelo Therapeutics GmbH are key players in the market.
Increasing prevalence of cancer across the globe coupled with rising aging population and growing preference for chemotherapy are factors driving market growth.
Neutropenia accounts for 61.6% share of the chemotherapy-induced myelosuppression treatment market.
The market is estimated to exhibit a CAGR of 3.3% during the forecast period (2022-2028).
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. FMI Analysis and Recommendations 1.4. Wheel of Fortune 2. Market Introduction 2.1. Market Taxonomy 2.2. Market Definition 2.3. Inclusion and Exclusions 3. Chemotherapy-Induced Myelosuppression Treatment Market Opportunity Analysis 3.1. Macro-Economic Factors 3.2. Opportunity Analysis 4. Market Background 4.1. Chemotherapy-Induced Myelosuppression Treatment Market Evolution 4.2. Market Dynamics 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Trends 5. Macroeconomic Assumptions 6. Global Economic Outlook 6.1. Gross Domestic Product by Region & Country, 2016 - 2021 7. Key Inclusions 7.1. Key Regulations 7.2. Pipeline Assessment 7.3. Patient Treatment Regimen/Patient Journey 8. Global Market Analysis 2013-2021 and Forecast 2022-2028 8.1. Market Value Share Analysis 8.2. Y-o-Y Growth Analysis 8.3. Absolute $ Opportunity 9. North America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028 9.1. Introduction 9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2021 9.2.1. U.S. 9.2.2. Canada 9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 9.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021 9.4.1. Growth Factors 9.4.1.1. Granulocyte Colony-Stimulating Factor 9.4.1.2. Thrombopoietin Receptor Agonists 9.4.2. Erythropoietin-stimulating Agents 9.4.3. Thrombopoietic Agents 9.4.4. Iron supplementation 9.4.5. Others 9.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 9.6.1. Oral 9.6.2. Injectable 9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 9.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021 9.8.1. Anemia 9.8.2. Neutropenia 9.8.3. Thrombocytopenia 9.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028 9.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 9.10.1. Hospital Pharmacies 9.10.2. Retail Pharmacies 9.10.3. Drug Stores 9.10.4. Online Pharmacies 9.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 9.12. Market Attractiveness Analysis 9.12.1. By Country 9.12.2. By Drug Class 9.12.3. By Route of Administration 9.12.4. By Indication 9.12.5. By Distribution Channel 9.13. Drivers and Restraints - Impact Analysis 10. Latin America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028 10.1. Introduction 10.2. Historical Market Size (US$ Mn) By Country, 2013-2021 10.2.1. Brazil 10.2.2. Mexico 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 10.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021 10.4.1. Growth Factors 10.4.1.1. Granulocyte Colony-Stimulating Factor 10.4.1.2. Thrombopoietin Receptor Agonists 10.4.2. Erythropoietin-stimulating Agents 10.4.3. Thrombopoietic Agents 10.4.4. Iron supplementation 10.4.5. Others 10.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 10.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 10.6.1. Oral 10.6.2. Injectable 10.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 10.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021 10.8.1. Anemia 10.8.2. Neutropenia 10.8.3. Thrombocytopenia 10.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028 10.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 10.10.1. Hospital Pharmacies 10.10.2. Retail Pharmacies 10.10.3. Drug Stores 10.10.4. Online Pharmacies 10.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 10.12. Market Attractiveness Analysis 10.12.1. By Country 10.12.2. By Drug Class 10.12.3. By Route of Administration 10.12.4. By Indication 10.12.5. By Distribution Channel 10.13. Drivers and Restraints - Impact Analysis 11. Western Europe Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028 11.1. Introduction 11.2. Historical Market Size (US$ Mn) By Country, 2013-2021 11.2.1. Germany 11.2.2. France 11.2.3. U.K. 11.2.4. Spain 11.2.5. Italy 11.2.6. Rest of Western Europe 11.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 11.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021 11.4.1. Growth Factors 11.4.1.1. Granulocyte Colony-Stimulating Factor 11.4.1.2. Thrombopoietin Receptor Agonists 11.4.2. Erythropoietin-stimulating Agents 11.4.3. Thrombopoietic Agents 11.4.4. Iron supplementation 11.4.5. Others 11.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 11.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 11.6.1. Oral 11.6.2. Injectable 11.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 11.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021 11.8.1. Anemia 11.8.2. Neutropenia 11.8.3. Thrombocytopenia 11.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028 11.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 11.10.1. Hospital Pharmacies 11.10.2. Retail Pharmacies 11.10.3. Drug Stores 11.10.4. Online Pharmacies 11.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 11.12. Market Attractiveness Analysis 11.12.1. By Country 11.12.2. By Drug Class 11.12.3. By Route of Administration 11.12.4. By Indication 11.12.5. By Distribution Channel 11.13. Drivers and Restraints - Impact Analysis 12. Eastern Europe Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028 12.1. Introduction 12.2. Historical Market Size (US$ Mn) By Country, 2013-2021 12.2.1. Russia 12.2.2. Poland 12.2.3. Rest of Eastern Europe 12.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 12.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021 12.4.1. Growth Factors 12.4.1.1. Granulocyte Colony-Stimulating Factor 12.4.1.2. Thrombopoietin Receptor Agonists 12.4.2. Erythropoietin-stimulating Agents 12.4.3. Thrombopoietic Agents 12.4.4. Iron supplementation 12.4.5. Others 12.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 12.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 12.6.1. Oral 12.6.2. Injectable 12.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 12.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021 12.8.1. Anemia 12.8.2. Neutropenia 12.8.3. Thrombocytopenia 12.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028 12.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 12.10.1. Hospital Pharmacies 12.10.2. Retail Pharmacies 12.10.3. Drug Stores 12.10.4. Online Pharmacies 12.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 12.12. Market Attractiveness Analysis 12.12.1. By Country 12.12.2. By Drug Class 12.12.3. By Route of Administration 12.12.4. By Indication 12.12.5. By Distribution Channel 12.13. Drivers and Restraints - Impact Analysis 13. Asia Pacific excluding China (APEC) Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028 13.1. Introduction 13.2. Historical Market Size (US$ Mn) By Country, 2013-2021 13.2.1. China 13.2.2. India 13.2.3. Australia and New Zealand 13.2.4. ASEAN 13.2.5. Rest of APAC 13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 13.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021 13.4.1. Growth Factors 13.4.1.1. Granulocyte Colony-Stimulating Factor 13.4.1.2. Thrombopoietin Receptor Agonists 13.4.2. Erythropoietin-stimulating Agents 13.4.3. Thrombopoietic Agents 13.4.4. Iron supplementation 13.4.5. Others 13.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 13.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 13.6.1. Oral 13.6.2. Injectable 13.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 13.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021 13.8.1. Anemia 13.8.2. Neutropenia 13.8.3. Thrombocytopenia 13.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028 13.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 13.10.1. Hospital Pharmacies 13.10.2. Retail Pharmacies 13.10.3. Drug Stores 13.10.4. Online Pharmacies 13.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 13.12. Market Attractiveness Analysis 13.12.1. By Country 13.12.2. By Drug Class 13.12.3. By Route of Administration 13.12.4. By Indication 13.12.5. By Distribution Channel 13.13. Drivers and Restraints - Impact Analysis 14. Japan Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021 14.2.1. Growth Factors 14.2.1.1. Granulocyte Colony-Stimulating Factor 14.2.1.2. Thrombopoietin Receptor Agonists 14.2.2. Erythropoietin-stimulating Agents 14.2.3. Thrombopoietic Agents 14.2.4. Iron supplementation 14.2.5. Others 14.3. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 14.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 14.4.1. Oral 14.4.2. Injectable 14.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 14.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021 14.6.1. Anemia 14.6.2. Neutropenia 14.6.3. Thrombocytopenia 14.7. Market Size (US$ Mn) Forecast By Indication, 2022-2028 14.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Drug Stores 14.8.4. Online Pharmacies 14.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 14.10. Market Attractiveness Analysis 14.10.1. By Drug Class 14.10.2. By Route of Administration 14.10.3. By Indication 14.10.4. By Distribution Channel 14.11. Drivers and Restraints - Impact Analysis 15. MEA Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028 15.1. Introduction 15.2. Historical Market Size (US$ Mn) By Country, 2013-2021 15.2.1. GCC Countries 15.2.2. South Africa 15.2.3. Rest of MEA 15.3. Market Size (US$ Mn) Forecast By Country, 2022-2028 15.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021 15.4.1. Growth Factors 15.4.1.1. Granulocyte Colony-Stimulating Factor 15.4.1.2. Thrombopoietin Receptor Agonists 15.4.2. Erythropoietin-stimulating Agents 15.4.3. Thrombopoietic Agents 15.4.4. Iron supplementation 15.4.5. Others 15.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 15.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 15.6.1. Oral 15.6.2. Injectable 15.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 15.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021 15.8.1. Anemia 15.8.2. Neutropenia 15.8.3. Thrombocytopenia 15.9. Market Size (US$ Mn) Forecast By Indication, 2022-2028 15.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 15.10.1. Hospital Pharmacies 15.10.2. Retail Pharmacies 15.10.3. Drug Stores 15.10.4. Online Pharmacies 15.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 15.12. Market Attractiveness Analysis 15.12.1. By Country 15.12.2. By Drug Class 15.12.3. By Route of Administration 15.12.4. By Indication 15.12.5. By Distribution Channel 15.13. Drivers and Restraints - Impact Analysis 16. Forecast Factors: Relevance and Impact 17. Forecast Assumptions 18. Competition Analysis 18.1. Competition Dashboard 18.2. Market Structure Analysis 18.3. Company Deep Dive 18.3.1. Amgen Inc. 18.3.1.1. Overview 18.3.1.2. Product and Application Portfolio 18.3.1.3. Production Footprint 18.3.1.4. Sales Footprint 18.3.1.5. Channel Footprint 18.3.1.6. Strategy 18.3.1.6.1. Marketing Strategy 18.3.1.6.2. Product Strategy 18.3.1.6.3. Channel Strategy 18.3.2. Novartis AG 18.3.3. Teva Pharmaceutical Industries Ltd 18.3.4. Mylan N.V. 18.3.5. Pfizer Inc. 18.3.6. Janssen Global Services, LLC (Johnson & Johnson) 18.3.7. Partner Therapeutics, Inc. 18.3.8. Mission Pharmacal Company 18.3.9. Myelo Therapeutics GmbH 18.3.10. Dova Pharmaceutical 19. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Region 19.1. Introduction / Key Findings 19.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013-2021 19.2.1. North America 19.2.2. Latin America 19.2.3. Western Europe 19.2.4. Eastern Europe 19.2.5. Asia Pacific excluding Japan 19.2.6. Japan 19.2.7. Middle East and Africa 19.2.8. Market Size (US$ Mn) Forecast By Region, 2022-2028 19.2.9. Market Attractiveness Analysis By Region 20. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Drug Class 20.1. Introduction 20.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013-2021 20.2.1. Growth Factors 20.2.1.1. Granulocyte Colony-Stimulating Factor 20.2.1.2. Thrombopoietin Receptor Agonists 20.2.2. Erythropoietin-stimulating Agents 20.2.3. Thrombopoietic Agents 20.2.4. Iron supplementation 20.2.5. Others 20.3. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028 20.4. Market Attractiveness Analysis By Drug Class 21. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Route of Administration 21.1. Introduction 21.2. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2021 21.2.1. Oral 21.2.2. Injectable 21.3. Market Size (US$ Mn) Forecast By Route of Administration, 2022-2028 21.4. Market Attractiveness Analysis By Route of Administration 22. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Indication 22.1. Introduction 22.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013-2021 22.2.1. Anemia 22.2.2. Neutropenia 22.2.3. Thrombocytopenia 22.3. Market Size (US$ Mn) Forecast By Indication, 2022-2028 22.4. Market Attractiveness Analysis By Indication 23. Global Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel 23.1. Introduction 23.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021 23.2.1. Hospital Pharmacies 23.2.2. Retail Pharmacies 23.2.3. Drug Stores 23.2.4. Online Pharmacies 23.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2022-2028 23.4. Market Attractiveness Analysis By Distribution Channel 24. Research Methodology
Healthcare
March 2022
REP-GB-1364
July 2022
211 pages
Healthcare
January 2022
REP-GB-8116
July 2022
207 pages
Explore Healthcare Insights
View Reports
Chemotherapy-Induced Myelosuppression Treatment Market
